# Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)

Source: https://onco.cc/trials/nct05949125/  
OnCo record `nct05949125` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of AVC-201 run by AvenCell Europe GmbH, now recruiting.

## Summary

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion) is a phase 1 interventional study registered as NCT05949125 by AvenCell Europe GmbH, with 37 participants planned, started 2024-01-03. Conditions recorded: Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory. Interventions recorded: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123 and Allo-RevCAR01-T.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05949125
- Phase: 1
- Setting: Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo RevCAR01 T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123
- Sponsor: AvenCell Europe GmbH
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT05949125: https://clinicaltrials.gov/study/NCT05949125

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [AVC-201](https://onco.cc/drugs/avc-201/)
- companies: [AvenCell Therapeutics](https://onco.cc/companies/avencell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05949125.json